| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01027923 Details | 2015-01-26 Interventional | 1 | 6 | Cytarabine Etoposide Mitoxantrone Plerixafor Leukemia Leukemia, Myelo… Leukemia, Myelo… | Withdrawal of support from sponsor - | |||
| NCT00646282 Details | 2015-01-26 Interventional | 4 | 12 | 1 alpha-hydroxy… Hyperparathyroi… Hyperparathyroi… | slow enrollment and discontinued once original principal investigator left Emory Due to slow enrollment and primary investigator leaving institution, the study was terminated. Subjects were notified and those on active drug returned to their physicians to be treated according to standard of care. | |||
| NCT00282165 Details | 2015-01-26 Interventional | 4 | 8 | Naratriptan Aggression Antisocial Pers… Disruptive, Imp… Personality Dis… Psychotic Disor… Impulse Regulat… Intermittent Ex… | Required number of subjects to be included could not be accomplished - | |||
| NCT01965301 2013-000697-30 Details | 2015-01-21 Interventional | 1 | 48 | Diphenhydramine Promethazine Healthy Male Vo… | - - | |||
| NCT01386398 2009-011021-13 Details | 2015-01-21 Interventional | 3 | 0 | Bortezomib Vorinostat Lymphoma | Company withdrew interest - | |||
| NCT00818675 Details | 2015-01-21 Interventional | 2 | 80 | Sirolimus Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | - - | |||
| NCT00060671 NCT00062361 Details | 2015-01-19 Interventional | 3 | [1 Refs] | - | Pixantrone Rituximab Lymphoma Lymphoma, Folli… Lymphoma, Non-H… Lymphoma, Low-G… Lymphoma, Mixed… Lymphoma, Small… | - - | ||
| NCT01777217 Details | 2015-01-16 Interventional | 4 | 8 | Solifenacin Suc… Urinary Bladder… Over-Active Bla… | Terminated Early termination leading to small numbers of subjects analyzed. | |||
| NCT00266357 Details | 2015-01-14 Interventional | 2 | - | Gaboxadol Sleep Initiatio… Primary Insomni… | - - | |||
| NCT00094666 Details | 2015-01-14 Interventional | 3 | - | Gaboxadol Sleep Initiatio… Primary Insomni… | - - | |||
| NCT00312650 Details | 2015-01-12 Interventional | 2 | - | Doxorubicin Gemcitabine Liposomal doxor… Carcinoma, Ovar… Ovarian Neoplas… Ovarian Carcino… | - - | |||
| NCT01772056 2008-005360-14 Details | 2015-01-09 Interventional | 3 | 54 | Fluticasone Dermatitis Dermatitis, Ato… | Patient recruitment is very slow, economic grant has ended and the number of patients is enough
according to sample size (22 children/ arm). - | |||
| NCT00209560 Details | 2015-01-09 Interventional | 3 | 168 | Fospropofol Carpal Tunnel S… Arthroscopy Bunionectomy Carpal Tunnel Osteotomy | - Analysis of results from a previous fospropofol study (3000-0410) completed during the enrollment of this study indicated that the dosing regimen needed to be re-evaluated. The study was prematurely terminated after 168 subjects were randomized. | |||
| NCT00975767 Details | 2015-01-08 Interventional | 1 | 126 | Docetaxel Erlotinib Hydro… Carcinoma, Non-… Lung Neoplasms Neoplasms Advanced Malign… | The study was terminated due to a need for a reformulation of the study drug. Phase 1
completed, no patients enrolled in Phase 2. - | |||
| NCT00511576 Details | 2015-01-08 Interventional | 1 | - | Docetaxel Mocetinostat Breast Neoplasm… Carcinoma, Non-… Lung Neoplasms Prostatic Neopl… Stomach Neoplas… Breast Cancer Gastric Cancer Lung Cancer Non-Small-Cell … Prostate Cancer Prostatic Cance… Pulmonary Cance… Stomach Cancer | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103.
All Celgene-sponsored trials with MGCD0103 will be closed. - | |||
| NCT02333851 Details | 2015-01-07 Interventional | 4 | 72 | Insulin, pork; … Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes… | Safety reasons - | |||
| NCT01224795 Details | 2015-01-06 Interventional | 3 | 1 | Peramivir Influenza, Huma… Influenza | This study was terminated for administrative reasons - | |||
| NCT01492920 Details | 2014-12-31 Interventional | 3 | 0 | Acetylcarnitine Brenner Tumor Carcinoma Carcinoma, Endo… Cystadenocarcin… Cystadenocarcin… Cystadenocarcin… Fallopian Tube … Neurotoxicity S… Peripheral Nerv… Recurrence Fatigue Malignant Ovari… Neuropathy Neurotoxicity S… Ovarian Brenner… Ovarian Clear C… Ovarian Endomet… Ovarian Mucinou… Ovarian Serous … Pain Recurrent Fallo… Recurrent Ovari… Recurrent Prima… | Withdrawn - | |||
| NCT01183455 Details | 2014-12-31 Interventional | 2 | 0 | Alpha 1-Antitry… Protease Inhibi… Diabetes Mellit… Diabetes Mellit… | Sponsor decision-lack of mechanistic signal and competing industry studies - | |||
| NCT00352859 Details | 2014-12-30 Interventional | 4 | 2 | Gemcitabine Interferons Sorafenib Carcinoma Carcinoma, Rena… | - - |